Table 2.

Characteristics of patients who developed virus-associated exacerbation stratified according to exacerbation frequency

	Frequent Exacerbators (n = 7)	Infrequent Exacerbators (n = 11)	P Value
Age, yr [median (IQR)]	69 (64–74)	71 (52–76)	0.84
Male sex	3 (42.9%)	9 (81.8%)	0.14
GOLD stage (median IQR)	2 (2–3)	2 (1–2)	0.13
Long-term oxygen	0 (0%)	0 (0%)	1.0
Cardiac disease	0 (0%)	1 (9.1%)	1.0
Cerebrovascular disease	1 (14.3%)	0 (0%)	0.39
Diabetes	1 (14.3%)	1 (9.1%)	1.0
Pulmonary hypertension	0 (0%)	0 (0%)	1.0
Inhaled corticosteroid use	4 (57.1%)	3 (27.3%)	0.33
Beta agonist use	6 (85.7%)	7 (63.6%)	0.60
Antimuscarinic inhaler use	4 (57.1%)	6 (54.5%)	1.0
Current smoker	4 (57.1%)	2 (18.2%)	0.14
Treatment during exacerbation
Antibiotics	5 (71.1%)	3 (27.3%)	0.15
Oral corticosteroids	3 (42.9%)	0 (0%)	0.043

GOLD, Global Initiative for Obstructive Lung Disease; IQR, interquartile range.